The pricing of this gene therapy has been much anticipated as it’s expected to set a precedent for future products.
SMA is a terrible disease where babies born with Type 1 are never able to sit independently and typically die before age 2. From my understanding, most of the babies in trial are still alive (after age 2) and most of them can sit independently. Really amazing outcomes.
To get a sense of the the SMA market is like, Biogen’s drug, Spinraza is priced at $750k for the first year and $375k for every year thereafter, for life.
So if this drug works for more than 5 years with a single dose, this $2M product will actually save the healthcare system money.
SMA is a terrible disease where babies born with Type 1 are never able to sit independently and typically die before age 2. From my understanding, most of the babies in trial are still alive (after age 2) and most of them can sit independently. Really amazing outcomes.
To get a sense of the the SMA market is like, Biogen’s drug, Spinraza is priced at $750k for the first year and $375k for every year thereafter, for life.
So if this drug works for more than 5 years with a single dose, this $2M product will actually save the healthcare system money.